Li Wei-Hua, Wei Zhuo-Wen, Liu Xiao-Feng
Department of Neurology.
Department of Anesthesiology, Baoji Traditional Chinese Medicine Hospital, Baoji.
Medicine (Baltimore). 2020 Nov 6;99(45):e23076. doi: 10.1097/MD.0000000000023076.
This study will appraise the clinical efficacy of sertraline in the treatment of depression caused by Alzheimer disease (AD).
Comprehensive searches in PUBMED, EMBASE, Cochrane Library, Scopus, AMED, CNKI, and WANGFANG will be performed from inception to the present without language restriction. In addition, other sources will also be searched to avoid losing more potential studies. We will only consider randomized controlled trials that examined the efficacy of sertraline for depression in patients with AD. Two team members will independently undertake literature selection, data collection, and risk of bias assessment. We will use Cochrane Risk of Bias Tool to assess the risk of bias for each eligible trial, and will utilize RevMan 5.3 software to carry out data analysis.
This study will recapitulate high-quality evidence to assess the efficacy of sertraline for the treatment of depression following AD.
The findings of this study will help to determine whether or not sertraline is effective for the treatment of depression after AD. OSF REGISTRATION:: osf.io/f29v6.
本研究将评估舍曲林治疗阿尔茨海默病（AD）所致抑郁症的临床疗效。
从数据库建立之初至目前，对PUBMED、EMBASE、Cochrane图书馆、Scopus、AMED、中国知网和万方数据库进行全面检索，无语言限制。此外，还将检索其他来源，以避免遗漏更多潜在研究。我们将仅纳入考察舍曲林治疗AD患者抑郁症疗效的随机对照试验。两名研究人员将独立进行文献筛选、数据收集和偏倚风险评估。我们将使用Cochrane偏倚风险工具评估每项合格试验的偏倚风险，并使用RevMan 5.3软件进行数据分析。
本研究将总结高质量证据，以评估舍曲林治疗AD后抑郁症的疗效。
本研究结果将有助于确定舍曲林治疗AD后抑郁症是否有效。开放科学框架注册：osf.io/f29v6。
